| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 28 | 2025 | 1088 | 1.790 |
Why?
|
| Carcinoma, Squamous Cell | 19 | 2019 | 1105 | 1.330 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2019 | 16 | 1.110 |
Why?
|
| Salivary Gland Neoplasms | 5 | 2019 | 85 | 1.100 |
Why?
|
| Oropharyngeal Neoplasms | 8 | 2025 | 152 | 1.060 |
Why?
|
| Otolaryngology | 2 | 2023 | 59 | 1.050 |
Why?
|
| Chemoradiotherapy | 15 | 2025 | 337 | 1.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 23 | 2025 | 2658 | 0.940 |
Why?
|
| Papillomavirus Infections | 8 | 2025 | 310 | 0.930 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2025 | 1535 | 0.780 |
Why?
|
| Otolaryngologists | 1 | 2023 | 5 | 0.770 |
Why?
|
| Actinomycosis | 1 | 2022 | 12 | 0.740 |
Why?
|
| Larynx | 1 | 2022 | 36 | 0.730 |
Why?
|
| Perforator Flap | 1 | 2020 | 12 | 0.630 |
Why?
|
| Paranasal Sinus Diseases | 2 | 2018 | 19 | 0.600 |
Why?
|
| Mouth Neoplasms | 7 | 2018 | 222 | 0.590 |
Why?
|
| Gene Rearrangement | 2 | 2019 | 175 | 0.590 |
Why?
|
| Nose Diseases | 1 | 2017 | 9 | 0.530 |
Why?
|
| Laryngeal Diseases | 2 | 2015 | 20 | 0.520 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 422 | 0.520 |
Why?
|
| Papillomaviridae | 6 | 2025 | 184 | 0.520 |
Why?
|
| Nose Neoplasms | 1 | 2017 | 38 | 0.510 |
Why?
|
| Maxillary Sinus | 2 | 2018 | 21 | 0.500 |
Why?
|
| Nasal Cavity | 1 | 2017 | 92 | 0.500 |
Why?
|
| Trans-Activators | 1 | 2019 | 447 | 0.490 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2016 | 30 | 0.460 |
Why?
|
| Aspergillosis | 1 | 2016 | 39 | 0.460 |
Why?
|
| Biomarkers, Tumor | 3 | 2025 | 1764 | 0.450 |
Why?
|
| Cementoma | 1 | 2015 | 1 | 0.450 |
Why?
|
| Mandibular Neoplasms | 1 | 2015 | 22 | 0.450 |
Why?
|
| Neoadjuvant Therapy | 5 | 2025 | 478 | 0.430 |
Why?
|
| Sarcoidosis | 1 | 2015 | 93 | 0.430 |
Why?
|
| Female | 59 | 2025 | 51535 | 0.420 |
Why?
|
| Middle Aged | 48 | 2025 | 29427 | 0.410 |
Why?
|
| Humans | 79 | 2025 | 98076 | 0.410 |
Why?
|
| Laryngeal Neoplasms | 5 | 2017 | 89 | 0.410 |
Why?
|
| ErbB Receptors | 5 | 2024 | 516 | 0.390 |
Why?
|
| Male | 56 | 2025 | 47075 | 0.380 |
Why?
|
| Sjogren's Syndrome | 3 | 2009 | 34 | 0.380 |
Why?
|
| Salivary Glands, Minor | 2 | 2009 | 9 | 0.380 |
Why?
|
| DNA, Viral | 2 | 2025 | 238 | 0.370 |
Why?
|
| Cetuximab | 3 | 2024 | 119 | 0.350 |
Why?
|
| Adult | 43 | 2025 | 29538 | 0.350 |
Why?
|
| Aged, 80 and over | 21 | 2020 | 7389 | 0.350 |
Why?
|
| Aged | 38 | 2025 | 21758 | 0.340 |
Why?
|
| Airway Management | 1 | 2012 | 53 | 0.330 |
Why?
|
| Carcinoma | 3 | 2022 | 440 | 0.320 |
Why?
|
| Paclitaxel | 8 | 2025 | 483 | 0.320 |
Why?
|
| Quinazolines | 4 | 2012 | 221 | 0.300 |
Why?
|
| Placenta | 1 | 2011 | 203 | 0.300 |
Why?
|
| Anesthesiology | 1 | 2012 | 171 | 0.300 |
Why?
|
| Hydroxyurea | 10 | 2022 | 233 | 0.290 |
Why?
|
| Leukoplakia, Oral | 2 | 2023 | 16 | 0.290 |
Why?
|
| Induction Chemotherapy | 6 | 2022 | 151 | 0.290 |
Why?
|
| Disease-Free Survival | 15 | 2020 | 1193 | 0.280 |
Why?
|
| Fluorouracil | 10 | 2022 | 541 | 0.270 |
Why?
|
| Diagnosis, Differential | 5 | 2024 | 1567 | 0.260 |
Why?
|
| Neck | 2 | 2020 | 103 | 0.260 |
Why?
|
| Head | 2 | 2020 | 135 | 0.250 |
Why?
|
| Radiotherapy, Intensity-Modulated | 5 | 2016 | 200 | 0.240 |
Why?
|
| Carboplatin | 6 | 2025 | 331 | 0.230 |
Why?
|
| Clinical Competence | 1 | 2012 | 865 | 0.230 |
Why?
|
| Radiotherapy Dosage | 11 | 2020 | 479 | 0.230 |
Why?
|
| Warts | 2 | 2019 | 12 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 882 | 0.220 |
Why?
|
| Macroglossia | 1 | 2024 | 7 | 0.220 |
Why?
|
| Tongue Neoplasms | 4 | 2018 | 51 | 0.220 |
Why?
|
| Ear Canal | 1 | 2024 | 16 | 0.210 |
Why?
|
| Ear Neoplasms | 1 | 2024 | 15 | 0.210 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2016 | 48 | 0.210 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2024 | 46 | 0.210 |
Why?
|
| Circulating Tumor DNA | 1 | 2025 | 82 | 0.200 |
Why?
|
| Antineoplastic Agents | 6 | 2012 | 2373 | 0.200 |
Why?
|
| Alphapapillomavirus | 2 | 2021 | 46 | 0.190 |
Why?
|
| Oral and Maxillofacial Surgeons | 1 | 2023 | 3 | 0.190 |
Why?
|
| Irritants | 1 | 2022 | 4 | 0.190 |
Why?
|
| Pharynx | 1 | 2022 | 43 | 0.180 |
Why?
|
| Treatment Outcome | 17 | 2022 | 9711 | 0.180 |
Why?
|
| Neoplasm Staging | 12 | 2016 | 2080 | 0.180 |
Why?
|
| Re-Irradiation | 1 | 2022 | 18 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2024 | 665 | 0.180 |
Why?
|
| HIV-1 | 1 | 2023 | 179 | 0.170 |
Why?
|
| Laryngostenosis | 1 | 2021 | 18 | 0.170 |
Why?
|
| Tracheal Stenosis | 1 | 2021 | 27 | 0.170 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2020 | 14 | 0.160 |
Why?
|
| Respiratory System | 1 | 2021 | 121 | 0.160 |
Why?
|
| Drug Monitoring | 1 | 2022 | 166 | 0.160 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2019 | 370 | 0.160 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 116 | 0.160 |
Why?
|
| Follow-Up Studies | 13 | 2019 | 4025 | 0.150 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 211 | 0.150 |
Why?
|
| ras Proteins | 1 | 2020 | 137 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1109 | 0.150 |
Why?
|
| Lymph Nodes | 2 | 2016 | 560 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 473 | 0.150 |
Why?
|
| Smoking | 3 | 2014 | 674 | 0.150 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 169 | 0.150 |
Why?
|
| Prospective Studies | 8 | 2025 | 4823 | 0.150 |
Why?
|
| Risk Factors | 8 | 2019 | 6232 | 0.150 |
Why?
|
| Arteries | 1 | 2020 | 171 | 0.150 |
Why?
|
| Thyroid Neoplasms | 2 | 2020 | 469 | 0.150 |
Why?
|
| Heterocyclic Compounds | 1 | 2019 | 21 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 4 | 2022 | 265 | 0.140 |
Why?
|
| Radiation Dosage | 1 | 2020 | 231 | 0.140 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2019 | 38 | 0.140 |
Why?
|
| Prognosis | 9 | 2022 | 4116 | 0.140 |
Why?
|
| Combined Modality Therapy | 9 | 2016 | 1751 | 0.140 |
Why?
|
| Receptors, CXCR4 | 1 | 2019 | 49 | 0.140 |
Why?
|
| Bone Cysts, Aneurysmal | 1 | 2018 | 7 | 0.140 |
Why?
|
| Lip | 2 | 2009 | 17 | 0.140 |
Why?
|
| United States | 7 | 2023 | 8196 | 0.140 |
Why?
|
| Young Adult | 6 | 2022 | 7507 | 0.140 |
Why?
|
| Precancerous Conditions | 2 | 2016 | 218 | 0.140 |
Why?
|
| Dental Alloys | 1 | 2018 | 5 | 0.140 |
Why?
|
| Orthodontic Appliances | 1 | 2018 | 7 | 0.140 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2018 | 73 | 0.130 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2016 | 86 | 0.130 |
Why?
|
| Deglutition | 3 | 2020 | 87 | 0.130 |
Why?
|
| Retrospective Studies | 15 | 2018 | 10972 | 0.130 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2017 | 3 | 0.130 |
Why?
|
| Glottis | 1 | 2017 | 13 | 0.130 |
Why?
|
| Child | 6 | 2019 | 7681 | 0.130 |
Why?
|
| Adolescent | 7 | 2022 | 10079 | 0.130 |
Why?
|
| Bone Marrow | 1 | 2019 | 418 | 0.130 |
Why?
|
| Inflammation | 2 | 2017 | 1120 | 0.130 |
Why?
|
| Life Style | 1 | 2018 | 193 | 0.120 |
Why?
|
| Hypopharyngeal Neoplasms | 2 | 2011 | 15 | 0.120 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 3021 | 0.120 |
Why?
|
| Professionalism | 1 | 2016 | 25 | 0.120 |
Why?
|
| Fibrosis | 1 | 2017 | 234 | 0.120 |
Why?
|
| Time Factors | 4 | 2019 | 5567 | 0.120 |
Why?
|
| Anticarcinogenic Agents | 1 | 2016 | 71 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 582 | 0.110 |
Why?
|
| Fibroma, Ossifying | 1 | 2015 | 5 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2017 | 250 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 1394 | 0.110 |
Why?
|
| Pleural Neoplasms | 1 | 2017 | 207 | 0.110 |
Why?
|
| Premedication | 1 | 1995 | 57 | 0.110 |
Why?
|
| Transcriptome | 1 | 2020 | 820 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1782 | 0.110 |
Why?
|
| Simulation Training | 1 | 2016 | 118 | 0.100 |
Why?
|
| Cerebellopontine Angle | 1 | 1994 | 10 | 0.100 |
Why?
|
| Ulnar Nerve | 1 | 1994 | 7 | 0.100 |
Why?
|
| Neuroma, Acoustic | 1 | 1994 | 20 | 0.100 |
Why?
|
| Tumor Virus Infections | 1 | 2014 | 83 | 0.100 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 1994 | 28 | 0.100 |
Why?
|
| Facial Nerve | 1 | 1994 | 35 | 0.100 |
Why?
|
| Aminolevulinic Acid | 1 | 2013 | 22 | 0.100 |
Why?
|
| Biopsy | 4 | 2009 | 1224 | 0.100 |
Why?
|
| HIV Infections | 1 | 2023 | 1018 | 0.100 |
Why?
|
| Photosensitizing Agents | 1 | 2013 | 53 | 0.100 |
Why?
|
| Monitoring, Intraoperative | 1 | 1994 | 115 | 0.100 |
Why?
|
| Mouth | 2 | 2011 | 53 | 0.090 |
Why?
|
| Photochemotherapy | 1 | 2013 | 101 | 0.090 |
Why?
|
| Pain | 1 | 2015 | 416 | 0.090 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2012 | 98 | 0.090 |
Why?
|
| Survival Analysis | 5 | 2018 | 1527 | 0.090 |
Why?
|
| Radiotherapy | 2 | 2011 | 325 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 449 | 0.090 |
Why?
|
| Lymph Node Excision | 1 | 2013 | 238 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 640 | 0.090 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2011 | 41 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2012 | 525 | 0.080 |
Why?
|
| Tracheotomy | 1 | 2011 | 18 | 0.080 |
Why?
|
| Deglutition Disorders | 2 | 2011 | 126 | 0.080 |
Why?
|
| Research Design | 2 | 2013 | 660 | 0.080 |
Why?
|
| Survival Rate | 4 | 2019 | 2041 | 0.080 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2024 | 137 | 0.080 |
Why?
|
| Speech | 1 | 2010 | 91 | 0.080 |
Why?
|
| Organ Preservation | 1 | 2011 | 139 | 0.080 |
Why?
|
| Brain Diseases | 1 | 2011 | 174 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2555 | 0.080 |
Why?
|
| Agammaglobulinemia | 1 | 2010 | 21 | 0.080 |
Why?
|
| Airway Obstruction | 1 | 2011 | 112 | 0.080 |
Why?
|
| Vocal Cords | 1 | 2009 | 27 | 0.080 |
Why?
|
| Developmental Disabilities | 1 | 2011 | 211 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2013 | 903 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2009 | 400 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2011 | 244 | 0.070 |
Why?
|
| Confidence Intervals | 4 | 2018 | 220 | 0.070 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2008 | 43 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2024 | 1099 | 0.070 |
Why?
|
| Neck Dissection | 4 | 2010 | 67 | 0.070 |
Why?
|
| Skin | 1 | 2012 | 591 | 0.070 |
Why?
|
| Cohort Studies | 5 | 2018 | 3212 | 0.070 |
Why?
|
| Enteral Nutrition | 2 | 2020 | 104 | 0.070 |
Why?
|
| Myelitis, Transverse | 1 | 2008 | 8 | 0.070 |
Why?
|
| Submandibular Gland Diseases | 1 | 2008 | 9 | 0.070 |
Why?
|
| Quality of Life | 3 | 2012 | 1895 | 0.070 |
Why?
|
| Neuromyelitis Optica | 1 | 2008 | 24 | 0.070 |
Why?
|
| Aortic Aneurysm | 1 | 1988 | 72 | 0.070 |
Why?
|
| Genomics | 1 | 2014 | 898 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 288 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2019 | 296 | 0.060 |
Why?
|
| Military Personnel | 1 | 2009 | 121 | 0.060 |
Why?
|
| Risk Assessment | 5 | 2016 | 2585 | 0.060 |
Why?
|
| Taxoids | 1 | 2007 | 127 | 0.060 |
Why?
|
| DNA | 1 | 2012 | 1274 | 0.060 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2006 | 22 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 1416 | 0.060 |
Why?
|
| Tinnitus | 1 | 2006 | 31 | 0.060 |
Why?
|
| Drug Administration Schedule | 4 | 2016 | 839 | 0.060 |
Why?
|
| Incidence | 3 | 2018 | 1779 | 0.060 |
Why?
|
| Headache | 1 | 2006 | 80 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1950 | 0.060 |
Why?
|
| Drug Therapy, Combination | 3 | 1999 | 764 | 0.060 |
Why?
|
| Prodrugs | 2 | 1996 | 53 | 0.060 |
Why?
|
| Cisplatin | 2 | 2022 | 578 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2011 | 2529 | 0.050 |
Why?
|
| Bevacizumab | 3 | 2011 | 255 | 0.050 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2024 | 8 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2024 | 73 | 0.050 |
Why?
|
| Mutation | 3 | 2024 | 4392 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 1211 | 0.050 |
Why?
|
| Gastroesophageal Reflux | 2 | 2009 | 129 | 0.050 |
Why?
|
| Pregnancy | 1 | 2011 | 3244 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2017 | 108 | 0.050 |
Why?
|
| Lamivudine | 1 | 2023 | 13 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 323 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 2666 | 0.050 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2023 | 55 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2017 | 1815 | 0.050 |
Why?
|
| Remission Induction | 2 | 2016 | 754 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2012 | 1123 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 127 | 0.040 |
Why?
|
| Retreatment | 2 | 2012 | 107 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2023 | 288 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 1565 | 0.040 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2021 | 8 | 0.040 |
Why?
|
| Alcohol Drinking | 2 | 2018 | 301 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2013 | 168 | 0.040 |
Why?
|
| Receptor, Endothelin A | 1 | 2021 | 21 | 0.040 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 237 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 55 | 0.040 |
Why?
|
| Lymphokines | 1 | 2001 | 74 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2021 | 163 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 211 | 0.040 |
Why?
|
| Periodontal Diseases | 1 | 2000 | 12 | 0.040 |
Why?
|
| Radiography | 2 | 2014 | 764 | 0.040 |
Why?
|
| Lymphoid Tissue | 1 | 2000 | 54 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2000 | 148 | 0.040 |
Why?
|
| Carcinoma, Papillary | 1 | 2001 | 165 | 0.040 |
Why?
|
| Disease Progression | 2 | 2017 | 1610 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2021 | 182 | 0.040 |
Why?
|
| Clindamycin | 2 | 1999 | 14 | 0.040 |
Why?
|
| Cefuroxime | 2 | 1996 | 3 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 801 | 0.040 |
Why?
|
| Tonsillectomy | 1 | 1999 | 32 | 0.040 |
Why?
|
| Benzylamines | 1 | 2019 | 17 | 0.040 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2019 | 19 | 0.040 |
Why?
|
| Aortic Rupture | 2 | 1990 | 53 | 0.040 |
Why?
|
| Bone Marrow Examination | 1 | 2019 | 40 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 233 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1999 | 87 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 480 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 320 | 0.030 |
Why?
|
| Primary Myelofibrosis | 1 | 2019 | 72 | 0.030 |
Why?
|
| Double-Blind Method | 3 | 2016 | 1782 | 0.030 |
Why?
|
| Oral Health | 1 | 2018 | 15 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1646 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 1009 | 0.030 |
Why?
|
| Receptor, trkC | 1 | 2017 | 6 | 0.030 |
Why?
|
| Myoepithelioma | 1 | 2017 | 10 | 0.030 |
Why?
|
| Laryngectomy | 1 | 2017 | 26 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2017 | 22 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 11 | 0.030 |
Why?
|
| Metals | 1 | 2018 | 104 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 302 | 0.030 |
Why?
|
| Parotid Gland | 1 | 2017 | 29 | 0.030 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2017 | 64 | 0.030 |
Why?
|
| Surgical Wound Infection | 2 | 1999 | 251 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 245 | 0.030 |
Why?
|
| Probability | 2 | 2008 | 356 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2017 | 160 | 0.030 |
Why?
|
| Otitis Media | 1 | 1996 | 20 | 0.030 |
Why?
|
| Everolimus | 1 | 2016 | 35 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 2020 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 84 | 0.030 |
Why?
|
| Otitis Media with Effusion | 1 | 1995 | 6 | 0.030 |
Why?
|
| Cutaneous Fistula | 1 | 1995 | 10 | 0.030 |
Why?
|
| Pyridines | 1 | 2017 | 318 | 0.030 |
Why?
|
| Cellulitis | 1 | 1995 | 17 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 3605 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 540 | 0.030 |
Why?
|
| Cephalosporins | 1 | 1995 | 27 | 0.030 |
Why?
|
| Dissection | 1 | 1995 | 48 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2014 | 22 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1995 | 155 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1138 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 674 | 0.030 |
Why?
|
| Drug Costs | 1 | 1995 | 66 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2014 | 45 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 55 | 0.030 |
Why?
|
| Hospital Costs | 1 | 1995 | 117 | 0.030 |
Why?
|
| Clavulanic Acids | 3 | 1999 | 3 | 0.020 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 3 | 1999 | 5 | 0.020 |
Why?
|
| Amoxicillin | 3 | 1999 | 12 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 201 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 682 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 1962 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 1994 | 340 | 0.020 |
Why?
|
| Rabbits | 1 | 1994 | 581 | 0.020 |
Why?
|
| Electromyography | 1 | 1994 | 233 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 200 | 0.020 |
Why?
|
| Platinum | 1 | 2012 | 68 | 0.020 |
Why?
|
| Aorta, Abdominal | 2 | 1990 | 57 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 2638 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 659 | 0.020 |
Why?
|
| Organ Sparing Treatments | 1 | 2011 | 52 | 0.020 |
Why?
|
| Supraglottitis | 1 | 2011 | 3 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2011 | 76 | 0.020 |
Why?
|
| Length of Stay | 1 | 1995 | 878 | 0.020 |
Why?
|
| Glutamates | 1 | 2011 | 84 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 216 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 246 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 272 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2011 | 153 | 0.020 |
Why?
|
| Leucovorin | 1 | 2010 | 205 | 0.020 |
Why?
|
| Guanine | 1 | 2011 | 194 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2010 | 191 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2012 | 373 | 0.020 |
Why?
|
| Osteoradionecrosis | 1 | 2010 | 18 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2011 | 217 | 0.020 |
Why?
|
| Camptothecin | 1 | 2010 | 198 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2010 | 321 | 0.020 |
Why?
|
| Siblings | 1 | 2010 | 113 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 300 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2009 | 66 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2009 | 193 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2009 | 49 | 0.020 |
Why?
|
| Syndrome | 1 | 2010 | 438 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 360 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 82 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 993 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 269 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1988 | 107 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 2010 | 184 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2009 | 166 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 1999 | 2681 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 1089 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 520 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 578 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2008 | 286 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 726 | 0.020 |
Why?
|
| Cranial Sinuses | 1 | 2006 | 21 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 551 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 1988 | 440 | 0.010 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1988 | 255 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 1032 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2006 | 239 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 1384 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 1988 | 387 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 3620 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2006 | 418 | 0.010 |
Why?
|
| Algorithms | 1 | 2011 | 2002 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 54 | 0.010 |
Why?
|
| Asthma | 1 | 2009 | 1078 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2006 | 1995 | 0.010 |
Why?
|
| Registries | 1 | 2006 | 1122 | 0.010 |
Why?
|
| Ticarcillin | 1 | 1999 | 1 | 0.010 |
Why?
|
| Mouthwashes | 1 | 1999 | 6 | 0.010 |
Why?
|
| Ampicillin | 1 | 1999 | 17 | 0.010 |
Why?
|
| Administration, Topical | 1 | 1999 | 80 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1999 | 212 | 0.010 |
Why?
|
| Infant | 2 | 1996 | 3328 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1996 | 4001 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1999 | 977 | 0.010 |
Why?
|
| Animals | 2 | 1994 | 28894 | 0.010 |
Why?
|
| Suspensions | 1 | 1996 | 6 | 0.010 |
Why?
|
| Bacteria | 1 | 1999 | 545 | 0.010 |
Why?
|
| Acute Disease | 1 | 1996 | 860 | 0.010 |
Why?
|
| Back Pain | 1 | 1990 | 76 | 0.000 |
Why?
|
| Hematoma | 1 | 1990 | 106 | 0.000 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1988 | 5 | 0.000 |
Why?
|
| Polytetrafluoroethylene | 1 | 1988 | 72 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1988 | 128 | 0.000 |
Why?
|
| Jugular Veins | 1 | 1988 | 65 | 0.000 |
Why?
|
| Omentum | 1 | 1988 | 69 | 0.000 |
Why?
|
| Microcirculation | 1 | 1988 | 101 | 0.000 |
Why?
|
| Dogs | 1 | 1988 | 639 | 0.000 |
Why?
|
| Aorta | 1 | 1988 | 275 | 0.000 |
Why?
|
| Thrombosis | 1 | 1988 | 318 | 0.000 |
Why?
|